PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
MDS
Advertisement
BrainStorm Advances NurOwn ALS Program Toward Phase 3b
New York, United States, August 14, 2026 BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter...
Kyowa Kirin Advances AI-Powered Drug Discovery R&D
Tokyo, Japan, August 16, 2026 Kyowa Kirin Co., Ltd. has selected Cognizant and Benchling as partners to implement an...
Actinium Advances Actimab-A With Manufacturing Expansion
New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...
Nabsys Partners With Indiana University on Cancer Genomics
PROVIDENCE, R.I., July 31, 2026 Nabsys 2.0, LLC has entered into a multi-year research collaboration with Indiana University School...
Advertisements
TScan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial
WALTHAM, Mass., July 29, 2026 TScan Therapeutics announced that the first patient has been dosed with TSC-101 in the...
Orca Bio Wins FDA Approval for TREGZI Cell Therapy
MENLO PARK, Calif., June 30, 2026 Orca Bio announced that the U.S. Food and Drug Administration (FDA) has approved...
TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Nabsys Expands OhmX Platform for AML and MDS Research
San Diego, California – May 17, 2026 Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM)...
Advertisement
